BNP PARIBAS FINANCIAL MARKETS - AGILE THERAPEUTICS INC ownership

AGILE THERAPEUTICS INC's ticker is AGRX and the CUSIP is 00847L100. A total of 51 filers reported holding AGILE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of AGILE THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$379,000
-58.0%
1,807
-2.3%
0.00%
Q4 2021$903,000
-51.3%
1,850
-4.1%
0.00%
Q3 2021$1,855,000
-27.7%
1,9300.0%0.00%
Q2 2021$2,567,000
-85.7%
1,930
-77.6%
0.00%
Q1 2021$17,911,000
-56.2%
8,611
-39.6%
0.00%
Q4 2020$40,929,000
-25.7%
14,261
-21.3%
0.00%
Q3 2020$55,112,000
+679.0%
18,129
+612.3%
0.00%
Q2 2020$7,075,000
+353650.0%
2,545
+254400.0%
0.00%
Q1 2020$2,0000.0%10.0%0.00%
Q4 2019$2,000
-60.0%
1
-75.0%
0.00%
Q3 2019$5,000
-16.7%
40.0%0.00%
Q2 2019$6,0000.0%40.0%0.00%
Q1 2019$6,000
-98.0%
4
-99.2%
0.00%
Q4 2018$301,000
+56.8%
5230.0%0.00%
Q3 2018$192,000
-25.6%
5230.0%0.00%
Q2 2018$258,000
-80.8%
5230.0%0.00%
Q1 2018$1,344,000
-4.5%
5230.0%0.00%
Q4 2017$1,407,000
-39.7%
5230.0%0.00%
Q3 2017$2,333,000
+19.0%
5230.0%0.00%
Q2 2017$1,961,000
+12.3%
523
-3.9%
0.00%
Q1 2017$1,746,000
+456.1%
544
+889.1%
0.00%
Q4 2016$314,000
-94.2%
55
-93.0%
0.00%
Q3 2016$5,458,000
+77.6%
782
+93.6%
0.00%
Q2 2016$3,074,000
-83.3%
404
-78.5%
0.00%
Q4 2015$18,368,000
+32.0%
1,882
-8.8%
0.00%
Q3 2015$13,911,000
+87.0%
2,064
+138.3%
0.00%
Q2 2015$7,439,0008660.00%
Other shareholders
AGILE THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
ProQuest Associates IV LLC 5,062,363$13,617,00018.09%
CAXTON CORP 1,820,012$4,896,0005.95%
Vivo Capital, LLC 1,513,975$4,073,0000.87%
Aisling Capital LLC 1,304,933$3,510,0000.69%
INVESTOR AB 3,510,189$9,442,0000.62%
Perceptive Advisors 3,380,000$9,092,0000.30%
NEEDHAM INVESTMENT MANAGEMENT LLC 408,838$1,099,0000.29%
Broadfin Capital, LLC 358,295$964,0000.16%
FALCON POINT CAPITAL, LLC 63,744$171,0000.03%
Monashee Investment Management LLC 16,411$44,0000.02%
View complete list of AGILE THERAPEUTICS INC shareholders